Velocity Pharmaceutical Development, Vitesse Biologics, Baxter, Mayo Clinic deal

Baxter’s Baxter Ventures arm, the Mayo Clinic and Velocity Pharmaceutical formed Vitesse Biologics, a newco that will develop antibody and protein-based therapies for immunology, hematology and oncology. Baxter’s BioScience unit, which is spinning out this year as Baxalta Inc., will have the exclusive option to acquire each program Vitesse develops following Phase I studies. ...